https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-24 / ESMO Open 2022 Feb;7(1):100334
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-24 / ESMO Open 2022 Feb;7(1):1003342021-12-24 00:00:002023-03-22 14:40:50Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-23 / Ther Adv Med Oncol 2021;13:17588359211064653
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-23 / Ther Adv Med Oncol 2021;13:175883592110646532021-12-23 00:00:002021-12-23 00:00:00Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-17 / Hum Vaccin Immunother 2021 Dec;17(12):5563-5572
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-17 / Hum Vaccin Immunother 2021 Dec;17(12):5563-55722021-12-17 00:00:002021-12-17 00:00:00Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-16 / Genes Dis 2023 Mar;10(2):430-446
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-16 / Genes Dis 2023 Mar;10(2):430-4462021-12-16 00:00:002021-12-16 00:00:00Oncolytic viruses: A novel treatment strategy for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-16 / Front Oncol 2021;11:789078
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-16 / Front Oncol 2021;11:7890782021-12-16 00:00:002021-12-16 00:00:00Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-14 / Acta Radiol 2023 Jan;64(1):32-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-14 / Acta Radiol 2023 Jan;64(1):32-412021-12-14 00:00:002023-01-31 12:51:13Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-10 / Pathol Oncol Res 2021;27:1610048
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-10 / Pathol Oncol Res 2021;27:16100482021-12-10 00:00:002021-12-10 00:00:00Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-12-03 / Clin Cancer Res 2021 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-12-03 / Clin Cancer Res 2021 Dec;2021-12-03 00:00:002021-12-03 00:00:00A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
